Form 4: Emergent BioSolutions SVP Disposes of Shares for Tax Withholding

Emergent BioSolutions Inc.'s SVP of Bioservices, William Hartzel, disposed of 1,167 shares of common stock on June 8, 2025, to cover tax obligations related to the vesting of restricted stock units.

Summary

• William Hartzel, Senior Vice President of Bioservices at Emergent BioSolutions Inc. (EBS), reported a transaction involving company common stock.
• On June 8, 2025, Mr. Hartzel disposed of 1,167 shares of common stock.
• The shares were disposed of at a price of $6.63 per share.
• This disposition was specifically for the purpose of paying taxes associated with the vesting and settlement of restricted stock units.
• Following this transaction, Mr. Hartzel beneficially owns 107,955 shares of Emergent BioSolutions common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, non-discretionary transaction for tax purposes related to executive compensation, with no direct positive or negative implications for the company's operational or financial performance.

Positives

• The transaction is a routine tax-related disposition, indicating the vesting of restricted stock units, which can be a positive for employee retention and compensation.

Negatives

• No specific negative financial or operational implications are indicated by this routine tax-related transaction.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a standard insider transaction filing (Form 4) related to executive compensation and tax obligations, common across all industries for publicly traded companies. It does not provide specific insights into broader industry trends or competitive dynamics within the biopharmaceutical sector.

Comparison to Industry Standards

• The disposition of shares for tax withholding upon vesting of restricted stock units is a common and standard practice for executive compensation across publicly traded companies, including those in the biopharmaceutical industry like Emergent BioSolutions. This type of transaction is routine and aligns with typical equity compensation plans.

Stakeholder Impact

• Shareholders: This is a routine transaction and is unlikely to have a significant direct impact on shareholders. It reflects standard executive compensation practices.
• Employees: The vesting of restricted stock units is a positive for the executive involved, reflecting a component of their compensation package.

Key Dates

Keywords

Emergent BioSolutions, EBS, Form 4, Insider Transaction, Stock Disposition, Tax Withholding, Restricted Stock Units, Executive Compensation